Swiss Life Asset Management Ltd Sells 12,896 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Swiss Life Asset Management Ltd lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 54.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 10,762 shares of the biopharmaceutical company’s stock after selling 12,896 shares during the quarter. Swiss Life Asset Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $8,307,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. WPG Advisers LLC boosted its holdings in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 25 shares during the last quarter. Board of the Pension Protection Fund bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. Caitlin John LLC bought a new position in Regeneron Pharmaceuticals during the third quarter worth about $34,000. FNY Investment Advisers LLC bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $38,000. Finally, Torren Management LLC bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $38,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $800.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, April 23rd. Barclays dropped their price target on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Sanford C. Bernstein dropped their price target on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating on the stock in a research report on Thursday, April 30th. Finally, Guggenheim raised their price target on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $826.59.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,330,604.99. The trade was a 49.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares in the company, valued at $12,343,815.72. This trade represents a 0.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Up 1.5%

Shares of Regeneron Pharmaceuticals stock opened at $723.41 on Wednesday. The business’s 50 day simple moving average is $748.97 and its 200 day simple moving average is $743.33. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The firm has a market cap of $76.48 billion, a PE ratio of 17.63, a P/E/G ratio of 1.58 and a beta of 0.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same quarter last year, the firm earned $8.22 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.1 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.